Oncotelic's AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif.

BIO-key (BKYI) Partners with Al Majlis Group, Founded by His Excellency Dherar Belhoul Al Falasi, to Expand Identity Security Across Arabian Gulf Region.

Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions.

Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

HOLMDEL, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and tokenless Identity-Bound Biometrics™ (IBB) authentication, today announced that its Passkey:YOU™ authenticator has received Full Certification from the FIDO Alliance, the industry body behind the FIDO2/WebAuthn/Passkey standard now in widespread use to allow phish-resistant sign in without typing a password.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relation.

California State Teachers Retirement System boosted its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 27,700.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,097,105 shares of the medical research company's stock after acquiring an additional 6,075,173 shares during the quarter.

Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript